Flavopiridol: Pleiotropic biological effects enhance its anti-cancer activity

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 411-419

  Newcomb, Elizabeth W ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti angiogenic agent; Anti proliferative activity; Combination therapy; Cyclin dependent kinase inhibitor; Flavopiridol

Indexed keywords

ADENOSINE TRIPHOSPHATE; CAMPTOTHECIN DERIVATIVE; CASPASE; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DOCETAXEL; FLAVOPIRIDOL; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; MATRIGEL; MATRIX METALLOPROTEINASE; MITOXANTRONE; PACLITAXEL; PROTEIN KINASE B; RITUXIMAB; SURVIVIN; THREONINE PROTEINASE; TRANSCRIPTION FACTOR E2F1; TRASTUZUMAB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; DOWN REGULATION; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME RELEASE; EXPERIMENTAL MODEL; GLIOMA; HEAD AND NECK CANCER; HUMAN; HYPOXIA; MITOCHONDRION; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; FLAVONOIDS; HUMANS; NEOPLASMS; PIPERIDINES;

EID: 2942582482     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127332.06439.47     Document Type: Review

References (64)

1. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Exp Opin Invest Drugs 2000; 9:2903-2911.
2. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001; 38:139-170.
3. Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updates 2003; 6:15-26.
4. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003; 22:6609-6620.
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-880.
6. de Azevedo Jr WF, Mueller-Dieckmann H-J, Schulze-Gahmen U, Worland PJ, Sausville E, Sung-Hou K. Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93:2735-2740.
7. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275:28345-28348.
8. de Azevedo Jr WF, Canduri F, da Silveira NJ. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002; 293:566-571.
9. Blagosklonny MV, Darzynkiewicz Z, Figg WD. Flavopiridol inversely affects p21WAF1/CIP1 and p53 protects p21-sensitive cells from paclitaxel. Cancer Biol Ther 2002; 1:420-426.
10. Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small lung cancer cell lines. Clin Cancer Res 1999; 5:2925-2938.
11. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003; 2:139-150.
12. Newcomb EW, Tamasdan C, Entzminger Y, Alonso J, Friedlander D, Crisan D, et al. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2003; 2:243-250.
13. Jiang J, Matranga CB, Cai D, Lathan Jr VM, Zhang X, Lowell AM, et al. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 2003; 63:7410-7422.
14. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process. Oncogene 2003; 22:7108-7122.
15. 1, cyclooxygenase-2 and matrix metalloprotease-9. J Biol Chem 2004; 279:4750-4759.
16. Javelaud D, Besancon F. Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J Biol Chem 2002; 277:37949-37954.
17. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, et al. Genome-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001; 2:1-11.
18. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002; 8:32-37.
19. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in non-cycling A549 human lung carcinoma cells. Cancer Res 1996; 56:4856-4861.
20. Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002; 62:1707-1717.
21. Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clin Cancer Res 2003; 9:4586-4594.
22. 34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63:230-235.
23. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 30:4307-4312.
24. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96:393-397.
25. WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemic cells. Mol Cancer Ther 2002; 1:253-266.
26. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8:3527-3538.
27. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Quo F, Yamaguchi H, et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003; 63:93-99.
28. Li Y, Bhuiyan M, Alhasan S, Senderowicz AM, Sarkar FH. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin Cancer Res 2000; 5:223-229.
29. Rapoport AP, Simons-Evelyn M, Chen T, Sidell R, Luhowskyj S, Rosell K, et al. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant P53 genes. Blood Cells Mol Dis 2001; 27:610-624.
30. Cartee L, Smith R, Dai Y, Rahmani M, Rosato R, Almenara J, et al. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Mol Pharmacol 2002; 61:1313-1321.
31. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003; 64:1822-1833.
32. Achenbach TV, Muller R, Slater EP. Bcl-2 independence of flavopiridol-induced apoptosis. J Biol Chem 2000; 275:32089-32097.
33. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
34. Orlowski RZ, Baldwin Jr AS. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002; 8:385-389.
35. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation, and tumor angiogenesis. Nature 1998; 394:485-490.
36. Brusselbach S, Nettlebeck DM, Sedlacek HH, Muller R. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1998; 77:146-152.
37. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22:8581-8589.
38. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156:393-398.
39. Harfouche R, Hassessian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD, et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 2002; 64:135-147.
40. Tran J, Master ZX, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99:4349-4354.
41. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a surivin mutant adenovirus. J Clin Investig 2001; 108:981-990.
42. v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999; 19:959-968.
43. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999; 59:5433-5437.
44. Rapella A, Negrioli A, Melillo G, Pastorino S, Varesio L, Bosco MC. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int J Cancer 2002; 99:658-664.
45. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62:4316-4324.
46. KIP-1 Clin Cancer Res 2000; 6:3006-3014.
47. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001; 7:4209-4219.
48. Newcomb EW, Tamasdan C, Entzminger Y, Arena E, Schnee T, Kim M et al. Flavopiridol inhibits the growth of GL261 gliomas in vivo: Implications for malignant glioma therapy. Cell Cycle 2004; 3:230-234.
49. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspies L, et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997; 3: 273-279.
50. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, et al. Flavopiridool induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91: 2482-2490.
51. Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998; 102:1674-1681.
52. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16:2986-2999.
53. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002; 50:465-472.
54. Lin TS, Howard OM, Neuberg DS, Kim HH, Shipp MA. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002; 43:793-797.
55. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000; 18:371-375.
56. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7:1590-1599.
57. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19: 1985-1992.
58. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003; 14:1270-1273.
59. Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002; 20:4074-4082.
60. Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, et al. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anticancer Drugs 2003; 14:125-135.
61. Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:1740-1745.
62. Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20:2157-2170
63. Raju U, Nakata E, Mason KA, Ang KK, Milas L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003; 63:3263-3267.
64. Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, et al. The cyclin-dependent inhibitor flavopiridol potentiates gamma-irradiation induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003; 9:6052-6061.